Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04517851 Phase I Elotuzumab Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis Recruiting USA 0
NCT04537715 Phase I Itraconazole + Tazemetostat Rifampin + Tazemetostat A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat Active, not recruiting USA | ESP 0
NCT04116502 Phase III Ruxolitinib Hydroxyurea Alpha 2 Interferon MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polcythemia Vera (MITHRIDATE) Recruiting 1
NCT02689336 Phase II Erlotinib + Temozolomide Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors Withdrawn 0
NCT04557956 Phase Ib/II Tazemetostat Dabrafenib + Tazemetostat + Trametinib Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment Recruiting USA 0
NCT04644211 Phase II Ruxolitinib Ruxolitinib in Thrombocythemia and Polycythemia Vera Not yet recruiting USA 0
NCT03854474 Phase Ib/II Pembrolizumab + Tazemetostat Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma Recruiting USA | CAN 0
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03571321 Phase I Pegaspargase Methotrexate Cytarabine Mercaptopurine Thioguanine Ruxolitinib Cyclophosphamide Dexamethasone Vincristine Sulfate Rituximab Doxorubicin Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia Recruiting USA 0
NCT02723994 Phase II Prednisone Dexamethasone + Doxorubicin Leucovorin Mercaptopurine + Thioguanine Asparaginase + Cytarabine Ruxolitinib Cyclophosphamide + Methotrexate + Pegaspargase + Vincristine Sulfate A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia Recruiting USA | CAN 2
NCT03801434 Phase II Ruxolitinib Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders Recruiting USA 0
NCT03613532 Phase I Busulfan + Fludarabine + Venetoclax Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN Recruiting USA 0
NCT02747537 Phase II Irinotecan + Sorafenib Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan Withdrawn 0
NCT01895842 Phase I Ruxolitinib Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Completed USA 0
NCT01164163 Phase I Ruxolitinib INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease Completed USA 0
NCT04409639 Phase II Cobimetinib Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations (CONCERTO) Recruiting USA 0
NCT03701295 Phase Ib/II Azacitidine + Pinometostat Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement Completed USA 0
NCT04517851 Phase I Elotuzumab Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis Recruiting USA 0
NCT04537715 Phase I Itraconazole + Tazemetostat Rifampin + Tazemetostat A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat Active, not recruiting USA | ESP 0
NCT04116502 Phase III Ruxolitinib Hydroxyurea Alpha 2 Interferon MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polcythemia Vera (MITHRIDATE) Recruiting 1
NCT02689336 Phase II Erlotinib + Temozolomide Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors Withdrawn 0
NCT04557956 Phase Ib/II Tazemetostat Dabrafenib + Tazemetostat + Trametinib Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment Recruiting USA 0
NCT04644211 Phase II Ruxolitinib Ruxolitinib in Thrombocythemia and Polycythemia Vera Not yet recruiting USA 0
NCT03854474 Phase Ib/II Pembrolizumab + Tazemetostat Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma Recruiting USA | CAN 0
NCT03601819 Phase I Pacritinib Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders Terminated USA 0